Triferic
Sponsors
Rockwell Medical Technologies, Inc.
Conditions
AnemiaChronic Kidney DiseaseEnd Stage Renal DiseaseIron-Refractory Iron-Deficiency AnemiaIron-refractory, Iron-deficiency Anemia (IRIDA)Peritoneal Dialysis (PD)
Phase 1
Triferic Pediatric Pharmacokinetic Protocol
CompletedNCT02595437
Start: 2015-11-01End: 2017-01-31Updated: 2018-10-25
Pharmacokinetics of Triferic (Ferric Pyrophosphate Citrate) Administered Intravenously to Healthy Adult Volunteers
CompletedNCT02636049
Start: 2015-10-31End: 2015-10-31Updated: 2019-08-20
Pharmacokinetics and Preliminary Bioequivalence of Triferic (Ferric Pyrophosphate Citrate) Administered Via Hemodialysate and Intravenously to Adult CKD-5HD Patients
CompletedNCT02739100
Start: 2016-04-30End: 2016-07-31Updated: 2019-02-01
Pharmacokinetics and Absolute Bioavailability of Fer-In-Sol and Triferic Administered Orally With Shohl's Solution in Healthy Volunteers
CompletedNCT02767128
Start: 2016-04-30End: 2016-04-30Updated: 2019-02-01
Study of Intraperitoneal Triferic in Patients on Chronic Peritoneal Dialysis
CompletedNCT02909153
Start: 2017-01-31End: 2017-07-31Updated: 2019-08-08
Equivalence of Triferic® (Ferric Pyrophosphate Citrate) Administered Via Hemodialysate and Intravenously to Adult CKD-5HD Patients
CompletedNCT03303144
Start: 2017-10-01End: 2017-12-28Updated: 2020-11-16
A Study to Investigate the Effect of Triferic Plus Heparin Infusion Compared to Heparin Alone on Coagulation Parameters in Hemodialysis Patients
CompletedNCT04042324
Start: 2019-09-30End: 2020-01-16Updated: 2020-12-02
Study to Investigate the Pharmacokinetic Comparability of Dosing Triferic AVNU IV by Continuous Infusion and IV Bolus.
CompletedNCT04409132
Start: 2020-06-25End: 2021-04-02Updated: 2021-07-13